Literature DB >> 19596443

The effect of amino acid substitution in the imperfect repeat sequences of alpha-synuclein on fibrillation.

Ryuichi Harada1, Natsuki Kobayashi, Jihoon Kim, Chikashi Nakamura, Sung-Woong Han, Kazunori Ikebukuro, Koji Sode.   

Abstract

Human alpha-synuclein is the causative protein of several neurodegenerative diseases, such as Parkinson's disease (PD) and dementia with Lewy Bodies (DLB). The N-terminal half of alpha-synuclein contains seven imperfect repeat sequences. One of the PD/DLB-causing point mutations, E46K, has been reported in the imperfect repeat sequences of alpha-synuclein, and is prone to form amyloid fibrils. The presence of seven imperfect repeats in alpha-synuclein raises the question of whether or not mutations corresponding to E46K in the other imperfect KTKE(Q)GV repeats have similar effects on aggregation and fibrillation, as well as their propensities to form alpha-helices. To investigate the effect of E(Q)/K mutations in each imperfect repeat sequence, we substituted the amino acid corresponding to E46K in each of the seven repeated sequences with a Lys residue. The mutations in the imperfect KTKE(Q)GV repeat sequences of the N-terminal region were prone to decrease the lag time of fibril formation. In addition, AFM imaging suggested that the Q24K mutant formed twisted fibrils, while the other mutants formed spherical aggregates and short fibrils. These observations indicate that the effect of the mutations on the kinetics of fibril formation and morphology of fibrils varies according to their location.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19596443     DOI: 10.1016/j.bbadis.2009.06.010

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  8 in total

1.  Coupling of the non-amyloid-component (NAC) domain and the KTK(E/Q)GV repeats stabilize the α-synuclein fibrils.

Authors:  Liang Xu; Ruth Nussinov; Buyong Ma
Journal:  Eur J Med Chem       Date:  2016-01-25       Impact factor: 6.514

Review 2.  Dynamic behaviors of α-synuclein and tau in the cellular context: New mechanistic insights and therapeutic opportunities in neurodegeneration.

Authors:  Fred Yeboah; Tae-Eun Kim; Anke Bill; Ulf Dettmer
Journal:  Neurobiol Dis       Date:  2019-07-24       Impact factor: 5.996

3.  Familial Mutations May Switch Conformational Preferences in α-Synuclein Fibrils.

Authors:  Liang Xu; Buyong Ma; Ruth Nussinov; Damien Thompson
Journal:  ACS Chem Neurosci       Date:  2017-01-27       Impact factor: 4.418

4.  Familial Parkinson's Disease Mutant E46K α-Synuclein Localizes to Membranous Structures, Forms Aggregates, and Induces Toxicity in Yeast Models.

Authors:  Michael Fiske; Michael White; Stephanie Valtierra; Sara Herrera; Keith Solvang; Alina Konnikova; Shubhik Debburman
Journal:  ISRN Neurol       Date:  2011-07-09

Review 5.  The Contribution of α-Synuclein Spreading to Parkinson's Disease Synaptopathy.

Authors:  Francesca Longhena; Gaia Faustini; Cristina Missale; Marina Pizzi; PierFranco Spano; Arianna Bellucci
Journal:  Neural Plast       Date:  2017-01-03       Impact factor: 3.599

Review 6.  Role of Apolipoproteins and α-Synuclein in Parkinson's Disease.

Authors:  Fatemeh Nouri Emamzadeh
Journal:  J Mol Neurosci       Date:  2017-07-10       Impact factor: 3.444

7.  Wildtype and A30P mutant alpha-synuclein form different fibril structures.

Authors:  Søren Bang Nielsen; Francesca Macchi; Samuele Raccosta; Annette Eva Langkilde; Lise Giehm; Anders Kyrsting; Anna Sigrid Pii Svane; Mauro Manno; Gunna Christiansen; Niels Christian Nielsen; Lene Oddershede; Bente Vestergaard; Daniel Erik Otzen
Journal:  PLoS One       Date:  2013-07-04       Impact factor: 3.240

8.  Excess membrane binding of monomeric alpha-, beta- and gamma-synuclein is invariably associated with inclusion formation and toxicity.

Authors:  Tae-Eun Kim; Andrew J Newman; Thibaut Imberdis; Lisa Brontesi; Arati Tripathi; Nagendran Ramalingam; Saranna Fanning; Dennis Selkoe; Ulf Dettmer
Journal:  Hum Mol Genet       Date:  2021-11-16       Impact factor: 6.150

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.